The 10-second takeaway
For the quarter ended March 31 (Q1), Covance met expectations on revenues and earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share increased.
Gross margins contracted, operating margins contracted, and net margins expanded.
Covance reported revenue of $530.8 million. The 13 analysts polled by S&P Capital IQ expected a top line of $531.9 million on the same basis. GAAP reported sales were 5.7% higher than the prior-year quarter's $502.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.60. The 17 earnings estimates compiled by S&P Capital IQ anticipated $0.60 per share. GAAP EPS of $0.60 for Q1 were 11% higher than the prior-year quarter's $0.54 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 29.1%, 50 basis points worse than the prior-year quarter. Operating margin was 8.7%, 80 basis points worse than the prior-year quarter. Net margin was 6.7%, 20 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $539.8 million. On the bottom line, the average EPS estimate is $0.64.
Next year's average estimate for revenue is $2.19 billion. The average EPS estimate is $2.66.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 312 members out of 321 rating the stock outperform, and nine members rating it underperform. Among 116 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 113 give Covance a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Covance is outperform, with an average price target of $48.46.
Over the decades, small-cap stocks like Covance have produced market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Covance to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Covance Inc. Shares Are Up 25% Today
Is this meaningful? Or just another movement?
4 Disruptive Stocks Biotechs Depend On
Contract research organizations Quintiles (Q), Icon PLC (ICLR), Covance (CVD), and Parexel (PRXL) are redefining how biopharma discovers and develops new therapies.
Covance Beats on the Top and Bottom Lines
Central lab services and clinical development programs boost efforts of contract services provider.